Lead Product(s) : THOR-707,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Synthorx
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : THOR-707, a precisely PEGylated, engineered version of IL-2 built on Sanofi’s Synthorin™ technology platform, is being studied in a trial of adults with advanced or metastatic solid tumors.
Product Name : THOR-707
Product Type : Protein
Upfront Cash : Inapplicable
September 04, 2021
Lead Product(s) : THOR-707,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Synthorx
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : THOR-707,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Sanofi
Deal Size : Undisclosed
Deal Type : Agreement
Sanofi Teams Up with Merck to Pair Keytruda with a Next-Gen IL-2 Candidate from the Synthorx Buyout
Details : The Phase 2 clinical trial aims to evaluate the safety, pharmacokinetics, and preliminary efficacy of THOR-707, a highly differentiated non-alpha IL-2 candidate combined with or in sequenced administration with MSD’s KEYTRUDA® (pembrolizumab) in patie...
Product Name : THOR-707
Product Type : Protein
Upfront Cash : Undisclosed
October 29, 2020
Lead Product(s) : THOR-707,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Sanofi
Deal Size : Undisclosed
Deal Type : Agreement
Sanofi announced today the successful completion of its acquisition of Synthorx, Inc
Details : Under the terms and conditions of the deal, Synthorx’ lead candidate THOR-707 is being tested against multiple tumour types, and will also be tested in combination with Sanofi’s own cancer drugs.
Product Name : THOR-707
Product Type : Protein
Upfront Cash : Undisclosed
January 23, 2020
Reset All
